How long on average can patients survive after taking apalutamide (Ansenko)?

Apalutamide (Apalutamide) is a new androgen receptor inhibitor used to treat castration-resistant prostate cancer (CRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Multiple clinical studies have shown that apalutamide has significant efficacy in delaying disease progression and improving patient survival expectations. After patients receive apalutamide treatment, they can significantly delay the occurrence of bone metastasis and metastasis to other organs, thus improving their quality of life.

According to data from key clinical trials of SPARTAN and TITAN In patients with prostate cancer, apalutamide can extend metastasis-free survival (MFS) to about 40 months, which is significantly higher than the placebo group. In addition, for patients with metastatic castration-resistant prostate cancer who receive apalutamide combined with standard endocrine therapy, their median overall survival (OS) can be prolonged by about 6 to 12 months. The specific prolongation time varies depending on the patient's age, underlying disease, and tumor load.

The efficacy of apalutamide is not only reflected in prolonging survival time, but also significantly reducing the risk of disease progression. For example, patients in the treatment group had an approximately 72% lower risk of developing bone metastases and an approximately 52% lower risk of systemic disease progression. This effect is particularly critical for late-stage patients, as it can delay disease progression, help patients maintain normal living abilities and reduce dependence on adjuvant treatment.

It should be noted that the survival benefit of apalutamide is closely related to individual patient differences, and the prolongation of efficacy may be affected by factors such as age, concomitant diseases, baseline tumor indicators, and medication compliance. Therefore, patients should regularly review relevant indicators while taking it, and adjust the course of treatment under the guidance of a professional doctor to obtain the best survival benefit and treatment effect.

Reference materials:https://www.drugs.com/